2022

1. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

   The Lancet Infectious Diseases, Vol. 22, Núm. 3, pp. 329-340

2. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

   eClinicalMedicine, Vol. 51

3. Inflammation biomarkers in suicide attempts and their relation to abuse, global functioning and cognition

   World Journal of Biological Psychiatry, Vol. 23, Núm. 4, pp. 307-317